Agnieszka Kiedik

Agnieszka Kiedik

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMagdalena Konieczny
Magdalena Konieczny
JSJolanta Sawicka
Jolanta Sawicka
IGIzabela Gąska
Izabela Gąska
EKElżbieta Kaczmar
Elżbieta Kaczmar
MPMałgorzata Pasek
Małgorzata Pasek
DKDorota Kiedik
Dorota Kiedik
Background: Emotional disturbances such as anxiety and depression are common in breast cancer patients and may intensify during systemic therapy. This study aimed to assess changes in the severity of anxiety and depression among women undergoing neoadjuvant chemotherapy and to identify factors influencing emotional outcomes. Methods: A total of 211 women with stage I–III breast cancer treated at the Podkarpackie Oncology Center in Brzozów, Poland, were included. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS) one week before and three weeks after chemotherapy. Statistical analyses were performed using the Wilcoxon signed-rank test and descriptive statistics (STATISTICA v.13). Results: After chemotherapy, anxiety and depression levels increased significantly. Nearly half of the patients experienced clinically relevant anxiety, and over one-third showed symptoms of depression. The emotional burden appeared particularly high among women reporting financial difficulties. In contrast, no clear associations were found with marital status, place of residence, or cancer stage. Conclusions: Chemotherapy in breast cancer patients is associated with a significant increase in anxiety and depression severity. Routine psychological assessment and psycho-oncological support should be implemented as integral components of oncological care, with particular attention to patients in disadvantaged socioeconomic conditions.

30 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
KZKacper Zima
Kacper Zima
AKAgnieszka Kiedik
Agnieszka Kiedik
ZPZuzanna Pietruk
Zuzanna Pietruk
JCJakub Chamier-Gliszczyński
Jakub Chamier-Gliszczyński
JKJulia Kozłowska
Julia Kozłowska
DPDominik Ryszard Płaza
Dominik Ryszard Płaza
Total joint arthroplasty (TJA) of the hip and knee is one of the most successful reconstructive procedures in modern orthopedics, providing significant pain relief and functional improvement. Over the past decades, a steady increase in the number of arthroplasty procedures performed in younger patients, commonly defined as individuals under 60 years of age, has been observed worldwide. This demographic shift poses unique clinical challenges, as younger patients present higher functional demands, longer life expectancy, and a substantially increased risk of revision surgery compared with elderly populations. The aim of this narrative review is to summarize current evidence regarding indications for total hip and knee arthroplasty in young patients, analyze perioperative and long-term risks, and discuss implant survivorship and functional outcomes. Furthermore, emerging technologies and treatment strategies designed to prolong implant longevity and delay revision surgery are reviewed. A comprehensive understanding of these factors is essential for appropriate patient selection, surgical planning, and long-term management of young individuals undergoing joint replacement.

14 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
ZPZuzanna Pietruk
Zuzanna Pietruk
MKMichał Kozicki
Michał Kozicki
PSPrzemysław Siemiątkowski
Przemysław Siemiątkowski
AKAgnieszka Kiedik
Agnieszka Kiedik
SSSylwia Skraińska
Sylwia Skraińska
KZKacper Zima
Kacper Zima
Background: Skin lesions are one of the common reasons for consultations in primary care (PC). Among them, skin cancers are a key clinical challenge, where early detection is crucial for the patient’s prognosis. Primary care physicians (PCPs) are responsible for the initial classification of skin conditions, determining which cases require referral to a specialist. In recent years, solutions using artificial intelligence (AI) have been gaining growing interest in medicine, offering new possibilities for diagnostic support, including in the field of dermatology. Objectives: The aim of this narrative review is to analyze the literature on whether and how artificial intelligence (AI) can support primary care physicians in the initial classification of skin lesions. Methods: A comprehensive review of the literature regarding the application of artificial intelligence in skin cancer diagnosis was conducted. The analysis covered results from clinical trials and reviews identifying implementation barriers. Key findings: Results from recent multicenter clinical trials demonstrate that Artificial Intelligence algorithms achieve high diagnostic sensitivity for melanoma, as well as robust accuracy for non-melanoma skin cancers. Comparative studies indicate that while AI performance is comparable to that of board-certified dermatologists, it statistically outperforms less experienced physicians. Conclusion: The conclusions from the study indicate that artificial intelligence can support primary care physicians by increasing their diagnostic effectiveness in the triage of skin lesions. As a support tool, it has the potential to reduce the risk of missing cancers while reducing the number of unreasonable referrals to specialists. However, a key condition for introducing these technologies into everyday clinical practice is to resolve identified ethical and technological barriers.

30 March 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DPDominik Ryszard Płaza
Dominik Ryszard Płaza
JCJakub Chamier-Gliszczyński
Jakub Chamier-Gliszczyński
ABAleksandra Boba
Aleksandra Boba
PSPrzemysław Siemiątkowski
Przemysław Siemiątkowski
KZKacper Zima
Kacper Zima
SSSylwia Skraińska
Sylwia Skraińska
Chemotherapy-induced alopecia (CIA) constantly remains one of the most noticeable and stress-inducing side-effects of cancer therapy, despite new strategies and advances in therapeutic approaches. Even though usually reversable, hair loss carries serious psychological and social consequences that affect patients’ comfort, social confidence and self-image, as well as adherence to oncological treatment. This review considers pathophysiological processes connected to CIA, focusing especially on anagen effluvium caused by cytotoxic nature of chemotherapeutic agents affecting proliferating hair follicle cells and underlines individual adaptation and susceptibility. Attention is focused particularly on controlled, mechanized scalp cooling method as an additional preventative intervention. Existing evidence from current studies clearly demonstrates that scalp cooling reduces the incidence and severity of CIA significantly, especially when it comes to taxane-based therapeutic regimens, with a range of 50% to 70% of hair preservation. In other types of therapies, like anthracycline-based, scalp cooling effectiveness is more limited but still shows meaningful reduction in severity and later onset of alopecia. Scalp cooling effectiveness reaches further than clinical outcomes. It contributes to an improved life quality, maintenance of privacy and identity and more positive patient-reported data. This review also takes global disparities, safety and ethical issues under consideration. Overall, innovative supportive strategies in medicine, like scalp cooling, integrate biological efficacy and psychological and social benefits and further underscore the importance of patient-focused approach in contemporary medicine, including oncological care.

30 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
SSSylwia Skraińska
Sylwia Skraińska
AKAgnieszka Kiedik
Agnieszka Kiedik
JKJulia Kozłowska
Julia Kozłowska
KZKacper Zima
Kacper Zima
ZPZuzanna Pietruk
Zuzanna Pietruk
PSPrzemysław Siemiątkowski
Przemysław Siemiątkowski
Background. Dermatomyositis (DM) is an idiopathic inflammatory myopathy in which characteristic cutaneous manifestations often precede or occur independently of muscle involvement. Skin findings are essential for diagnosis, phenotype classification and prognostic assessment, reflecting underlying immunopathologic processes. Aim of the study. To review and summarize current evidence on the spectrum of cutaneous manifestations in dermatomyositis, their associations with myositis-specific autoantibodies, and implications for prognosis, monitoring and management. Materials and methods. A narrative review of peer-reviewed literature was performed. Searches were conducted in PubMed and in the Medical University of Gdańsk (GUMed) online library catalog. Search terms included “dermatomyositis”, “cutaneous manifestations,” “autoantibodies” and related phenotype and outcome terms. Priority was given to recent cohort studies, key reviews and illustrative case series; articles in English and Polish were considered. Selected sources were synthesized qualitatively to describe clinical morphology, serologic correlations, validated skin assessment tools and therapeutic approaches. Conclusions. Classic cutaneous signs (heliotrope rash, Gottron papules/sign, shawl and V-neck distributions, poikiloderma) remain central to DM recognition. Distinct skin phenotypes correlate with specific autoantibodies (e.g., anti-MDA5 with ulcerations and high ILD risk; anti-TIF1-γ with extensive eruptions and malignancy association; anti-NXP2 with calcinosis). Standardized scoring (CDASI) aids objective assessment. Integrating detailed dermatologic evaluation with antibody profiling improves early diagnosis, risk stratification and individualized management. Prospective, phenotype-driven studies and refinement of classification criteria-particularly to better capture amyopathic variants-are needed.

29 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MKMagdalena Konieczny
Magdalena Konieczny
DKDorota Kiedik
Dorota Kiedik
JSJolanta Sawicka
Jolanta Sawicka
IGIzabela Gąska
Izabela Gąska
DBDorota Bądziul
Dorota Bądziul
ŁRŁukasz Rypicz
Łukasz Rypicz
Background/Objectives: Neoadjuvant chemotherapy is widely used in the treatment of breast cancer and improves oncological outcomes; however, its impact on patients’ psychosocial well-being remains insufficiently explored. This study aimed to assess changes in life satisfaction and self-esteem in women with breast cancer undergoing neoadjuvant chemotherapy. Methods: A prospective observational study was conducted among 211 women diagnosed with breast cancer and treated with neoadjuvant chemotherapy. Life satisfaction was assessed using the Satisfaction with Life Scale, and self-esteem was measured with the Rosenberg Self-Esteem Scale. Assessments were performed one week before initiation of chemotherapy and three weeks after its completion. Statistical analyses included descriptive statistics, the Wilcoxon signed-rank test, and Spearman correlation analysis. Results: A significant decrease in life satisfaction was observed after chemotherapy (mean 21.6 vs. 18.7; p < 0.001), indicating a shift from slight satisfaction to slight dissatisfaction. Self-esteem also significantly decreased (29.4 vs. 27.8; p < 0.001), although it remained within the average range. A decline in life satisfaction was reported in 60.7% of patients and a decrease in self-esteem in 50.2%. A significant positive correlation between life satisfaction and self-esteem was observed both before and after treatment. Financial status significantly differentiated both outcomes after chemotherapy. Conclusions: Neoadjuvant chemotherapy is associated with a significant decline in life satisfaction and self-esteem in women with breast cancer, highlighting its psychosocial impact. These findings support the need for routine assessment of psychological well-being and the integration of psycho-oncological support into comprehensive cancer care. Because the post-treatment assessment was performed shortly after chemotherapy completion, the findings primarily reflect short-term changes during treatment phase.